HIV infection, while highly treatable with current antiretroviral therapies, is not presently curable due to infection with copies of the virus that is hidden and cannot be eliminated with existing medications.
However, investigators are now conducting studies to see if certain chemotherapy drugs may have a possible role in treating HIV infection itself, since these therapies effect cell DNA. These therapies could potentially expose the hidden copies of the HIV virus which may then be attacked with effective antiretroviral therapy. The possible benefits and/or risks of this treatment, however, have not been adequately tested in humans, though several research studies are in progress or are being planned.
The UCLA CARE Center is conducting one such study to test the safety of an experimental therapy, given at different dose levels in combination with a standard chemotherapy combination often administered to cancer patients, to find out what effects, good and/or bad, it has on the participants and their cancer:
A Phase I study of vorinostat in combination with paclitaxel and carboplatin in solid tumors (with focus on upper aerodigestive cancers in person with HIV infection.
Phase I Trial of Carbozantinib (Xl184) for Advanced Solid Tumors in Persons with HIV Infection.
A Phase I study of Ipilimumab and Nivolumab in Advanced HIV-Associated Tumors with an Expansion Cohort in HIV Associated tumors.
For more information about the UCLA CARE Center's clinical trials and research studies, please contact: